Effects of 3,4-diaminopyridine on myasthenia gravis: Preliminary results of an open-label study

• Hoofdauteurs: Marco Ceccanti (Auteur), Laura Libonati (Auteur), Gabriele Ruffolo (Auteur), Pierangelo Cifelli (Auteur), Federica Moret (Auteur), Vittorio Frasca (Auteur), Eleonora Palma (Auteur), Maurizio Inghilleri (Auteur), Chiara Cambieri (Auteur)
• Formaat: Boek
• Gepubliceerd in: Frontiers Media S.A., 2022-08-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Background: 3,4-diaminopyridine (3,4-DAP) can lead to clinical and electrophysiological improvement in myasthenic syndrome; it may thus represent a valuable therapeutic option for patients intolerant to pyridostigmine.Objective: to assess 3,4-diaminopyridine (3,4-DAP) effects and tolerability in pat...